Acumen Pharmaceuticals, Inc.
sabirnetug (ACU193)
Alzheimer's Disease
Resolved
463days ago
Phase 1 readout · ~ Mar 31, 2025 estimated
What's at stake
Phase 1 trial results for sabirnetug (ACU193) in Alzheimer's Disease are due ~ Mar 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Phase 1 topline results announced March 2025 support further development”